Arantxa Sanz, CEO of Catalonia.health, participated in the European Health Summit in Brussels addressing how AI influences the interpretation of European health regulations. The study presented by LLYC reveals significant disparities in quality and access to information based on user profile and geography, emphasizing the need for reliable sources.

Catalonia.health, the association that brings together more than 240 companies and knowledge agents from across the health value chain in Catalonia, has opened the call for its annual awards. The awards, which will be announced during the Nit de Catalonia.health, recognise the career and outstanding contributions of one of the members of the ecosystem.

Catalonia.Health welcomes Marta Herrera as Head of Communications for the organisation. With this addition, we are strengthening our commitment to strategic communication in order to amplify the visibility and projection of the association's leadership, equipping ourselves with the capabilities to empower our community and ensure the impact of the valuable actions we generate together.

The technology centre Eurecat, a member of Catalonia.health, has received the IX National Congress of Entrepreneurial Scientists award for the development of a 3D-printed vascular stent.

The biotechnology company SpliceBio, a member of Catalonia.Health, has been selected as a finalist in several leading international awards in the life sciences sector. 

The life science venture capital Asabys, a member of Catalonia.health, has co-led a €37 million funding round for Qida, a provider of home-basedservices and products for senior well-being.

The pharmaceutical company Mitelos, a member of Catalonia.health, announced an exclusive licensing and distribution agreement with East Midlands Pharma (EM Pharma), a leading UK distributor of consumer health and OTC medical products.

The biopharmaceutical company ORYZON, a member of Catalonia.health, has announced that the first patient has been enrolled in RESTORE, its multi‑center,open‑label Phase Ib clinical trial of iadademstat in adults with sickle cell disease (SCD). 

Abzu, a member of Catalonia.health, and ADViRNA, a boutique U.S.-based CRO, are joining forces to develop novel siRNA therapeutics.

The venture capital company Asabys Partners, a member of Catalonia.health, and AltamarCAM  Partners, a global investment firm specialized in private markets, have reached an agreement to integrate Aliath Bioventures, a member of Catalonia.health, the life sciences team, into Asabys and to co-manage the Alta Life Sciences Spain I FCR fund.